Journal Articles
Little, Robert D., McKenzie, Jo, Srinivasan, Ashish, Hilley, Patrick, Gilmore, Robert B., Chee, Desmond, Sandhu, Manjeet, Saitta, Daniel, Chow, Elizabeth, Thin, Lena, Walker, Gareth J., Moore, Gregory T., Lynch, Kate, Andrews, Jane, An, Yoon K., Bryant, Robert V., Connor, Susan J., Garg, Mayur, Wright, Emily K., Hold, Georgina, Segal, Jonathan P., Boussioutas, Alex, De Cruz, Peter, Ward, Mark G. and Sparrow, Miles P. (2024). Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial. BMJ Open, 14 (7) e081787, 1-8. doi: 10.1136/bmjopen-2023-081787
Lim, Emily, Thai, Maxter, An, Yoon-Kyo, Hendy, Peter, Alchlaihawi, Mahmoud, Leong, Rupert, Connor, Susan, Ng, Watson, Gu, Bonita, Thin, Lena, Sparrow, Miles, Gilmore, Robert, Taylor, Kirstin, Sallis, Olivia, Andrews, Jane M., Daker, Charlotte, Gearry, Richard B., Wark, Gabrielle, Ghaly, Simon, Begun, Matt, Krishnaprasad, Krupa, Wu, Tianhong, Ruddick-Collins, Leonie, Schreiber, Veronika, Okano, Satomi, Radford-Smith, Graham, Schulberg, Julien, van Langenberg, Daniel and Begun, Jakob (2024). High technical success rate of endoscopic balloon dilatation reduces surgical requirement for patients with stricturing Crohn’s disease. GastroHep, 2024 (1) 3686618, 1-10. doi: 10.1155/2024/3686618
Tassone, Daniel, Kazi, Shamsul, Lee, Tanya, Gilmore, Robert and Ding, Nik (2024). Systematic review and meta‐analysis of endoscopic versus medical management of peptic ulcers with adherent clots. Journal of Gastroenterology and Hepatology, 39 (10), 2031-2042. doi: 10.1111/jgh.16611
Tambakis, George, Schildkraut, Tamar, Delaney, Isabella, Gilmore, Robert, Loebenstein, Moshe, Taylor, Andrew, Holt, Bronte, Tsoi, Edward H, Cameron, Georgina, Demediuk, Barbara, Miller, Ashley, Connell, William, Wright, Emily, Thompson, Alexander and Holmes, Jacinta (2023). Management of foreign body ingestion in adults: time to STOP and rethink endoscopy. Endoscopy International Open, 11 (12), E1161-E1167. doi: 10.1055/a-2201-6928
Gilmore, Robert, Tan, Lian, Fernandes, Richard, An, Yoon-Kyo and Begun, Jakob (2023). Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis. Journal of Crohn's and Colitis, 17 (12), 2033-2036. doi: 10.1093/ecco-jcc/jjad115
Gilmore, Robert, Lo, Sheng W., Cheong, Rachael, Karim, Syeda Tahiya, Farrah, Deborah, Kashkooli, Soleiman, Segal, Jonathan P. and Garg, Mayur (2023). Factors associated with long‐term healthcare expense and steroid exposure in patients admitted with acute severe ulcerative colitis. JGH Open, 7 (7), 482-486. doi: 10.1002/jgh3.12933
Tassone, Daniel, Gilmore, Robert, Lee, Tanya and Ding, Nik S. (2023). Letter: diagnostic delay in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 57 (10), 1203-1204. doi: 10.1111/apt.17483
Gilmore, Robert, Tassone, Daniel and Ding, Nik S. (2023). Letter: tofacitinib in the real world – do clinical trial data stand up?. Alimentary Pharmacology and Therapeutics, 57 (6), 745-746. doi: 10.1111/apt.17402
Lin, Lyman, Gilmore, Robert and Basnayake, Chamara (2023). GI snapshot: weight loss and altered bowel habit in a 72-year-old woman. Gut, 72 (11), gutjnl-2022. doi: 10.1136/gutjnl-2022-329084
Bradbury, Jack, Gilmore, Robert and Garg, Mayur (2022). Multifocal small bowel intussusception: an unusual presentation of a common problem. Gastroenterology, 162 (7), 1844-1846. doi: 10.1053/j.gastro.2022.02.041
Gilmore, Robert B., Taylor, Kirstin M., Morrissey, C. Orla and Gardiner, Bradley J. (2022). Cytomegalovirus in inflammatory bowel disease: a clinical approach. Internal Medicine Journal, 52 (3), 365-368. doi: 10.1111/imj.15085
Srinivasan, Ashish, Gilmore, Robert, van Langenberg, Daniel and De Cruz, Peter (2022). Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn’s disease. Therapeutic Advances in Gastroenterology, 15 ARTN 17562848211070940. doi: 10.1177/17562848211070940
De Gregorio, Michael, Lee, Tanya, Krishnaprasad, Krupa, Amos, Gregory, An, Yoon-Kyo, Bastian-Jordan, Matthew, Begun, Jakob, Borok, Nira, Brown, Dougal J. M., Cheung, Wa, Connor, Susan J., Gerstenmaier, Jan, Gilbert, Lauren E., Gilmore, Robert, Gu, Bonita, Kutaiba, Numan, Lee, Allan, Mahy, Gillian, Srinivasan, Ashish, Thin, Lena, Thompson, Alexander J., Welman, Christopher J., Yong, Eric X. Z., De Cruz, Peter, van Langenberg, Daniel, Sparrow, Miles P. and Ding, Nik S. (2021). Higher anti-tumor necrosis factor-α levels correlate with improved radiological outcomes in Crohn's perianal fistulas. Clinical Gastroenterology and Hepatology, 20 (6), 1306-1314. doi: 10.1016/j.cgh.2021.07.053
Gilmore, Robert, Hilley, Patrick, Srinivasan, Ashish, Choy, Matthew and De Cruz, Peter (2021). Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis. Journal of Crohn's and Colitis, 16 (1), 166-168. doi: 10.1093/ecco-jcc/jjab109
Gilmore, Robert, Hilley, Patrick, Srinivasan, Ashish, Choy, Matthew C., Grace, Josephine A. and de Cruz, Peter (2021). Tofacitinib Is Safe and Effective When Used in Combination With Infliximab for the Management of Refractory Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 19 (6), 1302-1303. doi: 10.1016/j.cgh.2020.07.046
Hilley, Patrick, Gilmore, Robert, Srinivasan, Ashish, Choy, Matthew and De Cruz, Peter (2021). Combined targeted treatment using biologic-tofacitinib co-therapy in chronic active ulcerative colitis. Inflammatory Bowel Diseases, 27 (9), e105-e106. doi: 10.1093/ibd/izab095
Gilmore, Robert, Li Wai Suen, Christopher F D, Elliott, Tim, De Cruz, Peter and Srinivasan, Ashish (2020). Using Ustekinumab to Treat Crohn’s Disease–Related Orofacial Granulomatosis: Two Birds, One Stone. Inflammatory Bowel Diseases, 26 (8), e79-e80. doi: 10.1093/ibd/izaa123
Gilmore, Robert, Choy, Matthew C, Li Wai Suen, Christopher F D and De Cruz, Peter (2020). Letter to the Editor: Antibiotic Cocktail for Pediatric Acute Severe Colitis and the Microbiome: The PRASCO Randomized Controlled Trial. Inflammatory Bowel Diseases, 26 (5), e41-e41. doi: 10.1093/ibd/izaa038
Conference Papers
Fernandes, Richard G., Khoo, Emi, Harris, Heidi Jensen, Gilmore, Robert, Khaing, Myat Myat, Begun, Jakob and An, Yoon-Kyo (2024). A Cost-effective Inflammatory Bowel Disease Flare Management Pathway Utilising Rapid Access Intestinal Ultrasound And Nurse-led Triage To Achieve Hospital Avoidance With High Patient Satisfaction. Digestive Disease Week (DDW) 2024, Chicago, IL United States, 18-21 May 2024. Philadelphia, PA United States: Elsevier BV. doi: 10.1016/s0016-5085(24)01652-4
Gilmore, R., Fernandes, R., Hartley, I., Arzivian, A., Leong, R., Andrew, B., Vasudevan, A., Greeve, T., Moore, G., Kim, S., Lightowler, D., Singh, A., Mahy, G., Mithanthaya, A., Venugpal, K., Han, S., Bryant, R., West, J., Segal, J., Christensen, B., Ding, N. J., An, Y. K. and Begun, J. (2024). Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to Tofacitinib. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.1194
Gilmore, R., Fernandes, R., Hartley, I., Arzivian, A., Leong, R., Andrew, B., Vasudevan, A., Greeve, T., Moore, G., Kim, S., Lightowler, D., Singh, A., Mahy, G., Mithanthaya, A., Venugpal, K., Han, S., Bryant, R., West, J., Segal, J., Christensen, B., Ding, N. J., An, Y. K. and Begun, J. (2024). Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to Tofacitinib. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.1194
Fernandes, R., Khoo, E., Harris, H., Gilmore, R., Khaing, M., Begun, J., An, Y. K. and Mater IBD Research Group (2024). A cost-effective Inflammatory Bowel Disease flare management pathway utilising rapid access intestinal ultrasound and nurse-led triage to achieve hospital avoidance with increased patient satisfaction. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0750
Gilmore, R., Fernandes, R., Hartley, I., Arzivian, A., Leong, R., Andrew, B., Vasudevan, A., Greeve, T., Moore, G., Kim, S., Lightowler, D., Singh, A., Mahy, G., Mithanthaya, A., Venugopal, K., Han, S., Bryant, R., Corte, C., Ding, J. N., An, Y-K and Begun, J. (2023). Australian multicenter real-world experience of upadacitinib induction therapy for moderate to severe ulcerative colitis. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons.
Tan, W. L., Gilmore, R., Huang, A., Fernandes, R., An, Y-K and Begun, J. (2023). Upadacitinib for rescue therapy in patients with acute severe ulcerative colitis: An Australian real-world experience. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons.
Fernandes, R., Harris, H., Khoo, E., Gilmore, R., Howlett, M., Walker, N., Hendy, P., Begun, J. and An, Y-K (2023). Reducing hospital resource utilization and improving patient satisfaction with an innovative inflammatory bowel disease nurse-led clinical care pathway with rapid-access intestinal ultrasound. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. HOBOKEN: WILEY.
Anandan, A. Shanmuga, Fernandes, R., Etchegaray, A., Malloy, R., Selvanathan, P., Gilmore, R., Pham, H., Begun, J. and An, Y-K (2023). Vedolizumab has longer persistence than infliximab for ulcerative colitis in a real-world cohort study: Preliminary results from the COMPARE-IT study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons.
Fernandes, R., Gilmore, R., Ruddick-Collins, L., Rice, K., Moore, G., Gazelakis, K., Vasudevan, A., Zhang, J., Wright, E., Schildkraut, T., Clark, N., Schultz, M., Brownson, A., Haifer, C., Bracken, L. M. L., Mahy, G., Swe, E., Judge, C., Ngoi, B., Lynch, K., Begun, J. and An, Y-K (2023). Cessation of corticosteroids after acute severe ulcerative colitis may be associated with increased colectomy risk: Results of the ANZ-ASUC study in collaboration with the ANZIBDC. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons.
Etchegaray, A., Gilmore, R., An, Y-K and Begun, J. (2023). Upadacitinib and vedolizumab combination therapy for recalcitrant, steroid-refractory Crohn's disease: A case report. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons.
Gilmore, R., Fernandes, R., Schildkraut, T., Joshi, R., Lin, L., Etchegaray, A., Anandan, A. Shanmuga, Begun, J., An, Y-K and Wright, E. (2023). Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons.
Fernandes, R., Gilmore, R., Ruddick-Collins, L., Rice, K., Gazelakis, K., Moore, G., Vasudevan, A., Zhang, J., Wright, E., Schildkraut, T., Clark, N., Schultz, M., Brownson, A., Haifer, C., Bracken, L. M. L., Mahy, G., Swe, E., Lynch, K., Ngoi, B., Judge, C., Kim, D. H., Kim, H. S., Lee, H. S., Kim, K. O., Lee, Y. J., Kim, S-J, Lee, J., Song, E. M., Park, S. H. ... An, Y-K (2023). Patients from East Asia with acute severe ulcerative colitis have worse endoscopic severity but are more responsive to intravenous steroids than patients from Australasia: Preliminary results of the APAC-ASUC study in collaboration with the ANZIBDC and AOCC. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons.
Etchegaray, A., Fernandes, R., Anandan, A. Shanmuga, Selvanathan, P., Malloy, R., Gilmore, R., Pham, H., Begun, J. and An, Y-K (2023). Real-world study finds similar effectiveness of biologics but higher durability of ustekinumab in patients with Crohn's disease: Preliminary results from the COMPARE-IT Crohn's disease study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons.
Lim, E., Thai, M., Hendy, P., Alchlaihawi, M., Leong, R., Connor, S., Ng, W., Gu, B., van Langenberg, D., Thin, L., Schulberg, J., Kamm, M., Gilmore, R., Taylor, K., Sallis, O., Andrews, J., Daker, C., Barclay, M., Wark, G., Ghaly, S., Begun, M., Krishnaprasad, K. and Begun, J. (2019). Endoscopic balloon dilatation is safe and has a high success rate in patients with stricturing Crohn's disease. 14th Congress of ECCO, Copenhagen, Denmark, 6-9 March 2019. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjy222.647